Agiliti Announces Financial Results for Third Quarter 2022

Rhea-AI Summary

Agiliti Inc. (NYSE: AGTI) reported its Q3 2022 financial results, revealing a 3% revenue growth to $271 million. However, net income fell $7.7 million year-over-year, totaling $2 million, and diluted EPS decreased by $0.06 to $0.01. Adjusted EBITDA also declined by 18.9% to $66.5 million. Despite a 12.2% revenue increase for the nine months ended September 30, 2022, the company revised its full-year guidance to $1.11 - $1.12 billion in revenue and $290-300 million in adjusted EBITDA, reflecting a cautious outlook.

Positive

• Q3 2022 revenue of $271 million, a 3.3% increase year-over-year.
• 9-month revenue of $839.6 million, representing a 12.2% increase year-over-year.
• Long-term growth strategy remains intact despite short-term headwinds.

Negative

• Net income decreased by $7.7 million year-over-year to $2 million.
• Diluted EPS fell by $0.06 to $0.01 compared to the prior year.
• Adjusted EBITDA decreased by 18.9% to $66.5 million.

MINNEAPOLIS--(BUSINESS WIRE)-- Agiliti Inc. (NYSE: AGTI) (“Agiliti”), a nationwide provider of healthcare technology management and service solutions to the United States healthcare industry, today announced its financial results for the quarter ended September 30, 2022, and revised its full-year financial guidance.

Third Quarter 2022 Highlights

• Revenue growth of 3 percent to $271 million
• Net income of $2.0 million, down $7.7 million from the prior year period; diluted income per share of $0.01, down $0.06 per share from the prior year period
• Adjusted EBITDA¹ of $66.5 million, down $15.5 million compared to the prior year period; Adjusted Earnings Per Share¹ of $0.19, down $0.04 compared to the prior year period
• Total debt of $1.07 billion; Net debt¹ of $1.04 billion; and, Net Leverage ratio¹ of 3.3x

“Our results for the third quarter met our expectations and reflect our continued, organic growth momentum,” said Tom Leonard, CEO of Agiliti. “Our team continues to power our progress by focusing on our customers’ evolving needs and delivering some of the most significant new business deals in the company’s history. While we are encouraged by these positive developments, we are taking a more conservative view on the balance of the year as we manage through short-term headwinds related to the delayed HHS contract and the onboarding of a higher proportion of larger-scale contracts. Our long-term growth strategy remains intact, and we remain well positioned to weather any macro uncertainty ahead of us.”

Third Quarter 2022 Financial Results

Total revenue for the three months ended September 30, 2022, was $271.2 million, representing a 3.3 percent increase from total revenue of $262.4 million for the same period of 2021. Total revenue for the nine months ended September 30, 2022, was $839.6 million, representing a 12.2 percent increase from total revenue of $748.2 million for the same period of 2021.

Net income for the three months ended September 30, 2022, was $2.0 million, a $7.7 million decrease from the same period of 2021. Net income for the nine months ended September 30, 2022, was $26.8 million, a $12.8 million increase from net income of $14.0 million for the same period of 2021.

Adjusted EBITDA¹ for the three months ended September 30, 2022, was $66.5 million, a 18.9 percent decrease from Adjusted EBITDA¹ of $81.9 million for the same period of 2021. Adjusted EBITDA¹ for the nine months ended September 30, 2022, was $225.2 million, a 8.4 percent decrease from Adjusted EBITDA¹ of $245.8 million for the same period of 2021.

2022 Financial Guidance

The company revises its guidance for 2022 as follows:

• Revenue of $1.11 - $1.12 billion
• Adjusted EBITDA of $290-300 million²
• Adjusted earnings per share of $0.83 – $0.88 per share²
• Capex investment expected in the range of $75 to $85 million

_________________________

1. Non-GAAP Measures. See further discussion below.
2. With regard to the non-GAAP Adjusted EBITDA guidance and adjusted earnings per share guidance provided above, a reconciliation to GAAP net income has not been provided as the quantification of certain items included in the calculation of GAAP net income cannot be calculated or predicted at this time without unreasonable efforts. For example, the non-GAAP adjustment for stock-based compensation expense requires additional inputs such as number of shares granted and market price that are not currently ascertainable, and the non-GAAP adjustment for certain reserves and expenses depends on the timing and magnitude of these expenses and cannot be accurately forecasted. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could have a potentially unpredictable, and potentially significant, impact on its future GAAP financial results. See further discussion below regarding historical Adjusted EBITDA and historical adjusted earnings per share.

Conference Call Information

Agiliti will hold a conference call to discuss its third quarter 2022 results on Thursday, November 10, at 5 p.m. Eastern Time (4 p.m. Central Time).

The conference call can be accessed live over the phone by dialing 1-877-344-3030 or for international callers, 1-646-307-1984. A replay will be available two hours after the call and can be accessed by dialing 1-800-770-2030, or for international callers, 1-647-362-9199. The passcode for the live call and the replay is 8853057. The replay will be available until November 17, 2022.

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by visiting the Agiliti Investor Relations site at https://investors.agilitihealth.com. The online replay will be available for a limited time shortly following the call.

About Agiliti

Agiliti is an essential service provider to the U.S. healthcare industry with solutions that help support a more efficient, safe and sustainable healthcare delivery system. Agiliti serves more than 9,000 national, regional and local acute care and alternate site providers across the U.S. For more than eight decades, Agiliti has delivered medical equipment management and service solutions that help healthcare providers reduce costs, increase operating efficiencies and support optimal patient outcomes.

Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release are forward-looking in time, including financial outlook and other preliminary results, and involve risks and uncertainties. The following factors, among others, could adversely affect our business, operations and financial condition causing our actual results to differ materially from those expressed in any forward-looking statements: our history of net losses and substantial interest expense; our need for substantial cash to operate and expand our business as planned; our substantial outstanding debt and debt service obligations; restrictions imposed by the terms of our debt; a decrease in the number of patients our customers are serving; our ability to effect change in the manner in which health care providers traditionally procure medical equipment; the absence of long-term commitments with customers including our agreement with HHS/ASPR; our ability to renew contracts with group purchasing organizations and integrated delivery networks; changes in reimbursement rates and policies by third-party payors; the impact of health care reform initiatives; the impact of significant regulation of the health care industry and the need to comply with those regulations; the effect of prolonged negative changes in domestic and global economic conditions; difficulties or delays in our continued expansion into certain of our businesses/geographic markets and developments of new businesses/geographic markets; additional credit risks in increasing business with home care providers and nursing homes, impacts of equipment product recalls or obsolescence; increases in vendor costs that cannot be passed through to our customers; and other Risk Factors as detailed in our annual report on Form 10-K.

Agiliti, Inc. and Subsidiaries Consolidated Statements of Operations (in thousands, except share and per share information) (unaudited)
	Three Months Ended September 30,							Nine Months Ended September 30,
		2022				2021			2022				2021
Revenue	$	271,185			$	262,424		$	839,613			$	748,212
Cost of revenue		169,582				158,990			516,218				444,346
Gross margin		101,603				103,434			323,395				303,866
Selling, general and administrative expense		86,044				75,052			254,303				225,334
Operating income		15,559				28,382			69,092				78,532
Loss on extinguishment of debt		—				—			1,418				10,116
Interest expense		12,531				10,711			34,456				40,444
Tax indemnification expense		11,918				—			11,918				—
Income (loss) before income taxes and noncontrolling interest		(8,890	)			17,671			21,300				27,972
Income tax (benefit) expense		(10,879	)			7,943			(5,672	)			13,832
Consolidated net income		1,989				9,728			26,972				14,140
Net income attributable to noncontrolling interest		38				60			131				117
Net income attributable to Agiliti, Inc. and Subsidiaries	$	1,951			$	9,668		$	26,841			$	14,023
Basic income per share	$	0.01			$	0.07		$	0.20			$	0.12
Diluted income per share	$	0.01			$	0.07		$	0.19			$	0.11
Weighted-average common shares outstanding:
Basic		133,212,218				130,380,551			132,313,218				117,578,750
Diluted		139,062,813				138,490,526			138,242,880				125,515,000

Agiliti, Inc. and Subsidiaries Consolidated Balance Sheets (in thousands, except share and per share information) (unaudited)
	September 30, 2022				December 31, 2021
Assets
Current assets:
Cash and cash equivalents	$	32,211			$	74,325
Accounts receivable, less allowance for credit losses of $3,496 and $2,902		203,087				209,308
Inventories		60,987				55,307
Prepaid expenses		21,503				18,549
Other current assets		13,003				395
Total current assets		330,791				357,884
Property and equipment, net		253,639				258,370
Goodwill		1,218,329				1,213,121
Operating lease right-of-use assets		82,838				80,676
Other intangibles, net		508,769				573,159
Other		23,295				32,537
Total assets	$	2,417,661			$	2,515,747
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	17,642			$	17,534
Current portion of operating lease liability		23,438				22,826
Current portion of obligation under tax receivable agreement		29,824				29,187
Accounts payable		59,094				53,851
Accrued compensation		31,867				47,951
Accrued interest		3,889				3,473
Deferred revenue		9,279				5,808
Other accrued expenses		25,883				27,900
Total current liabilities		200,916				208,530
Long-term debt, less current portion		1,050,288				1,174,968
Obligation under tax receivable agreement, pension and other long-term liabilities		17,036				29,629
Operating lease liability, less current portion		70,259				63,241
Deferred income taxes, net		142,676				143,307
Commitments and contingencies
Equity:
Common stock, $0.0001 par value; 500,000,000 shares authorized; 133,330,184 and 130,950,061 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively		13				13
Additional paid-in capital		944,477				938,888
Accumulated deficit		(17,645	)			(44,486	)
Accumulated other comprehensive income		9,490				1,537
Total Agiliti, Inc. and Subsidiaries equity		936,335				895,952
Noncontrolling interest		151				120
Total equity		936,486				896,072
Total liabilities and equity	$	2,417,661			$	2,515,747

Agiliti, Inc. and Subsidiaries Consolidated Statements of Cash Flows (in thousands) (unaudited)
	Nine Months Ended September 30,
		2022				2021
Cash flows from operating activities:
Consolidated net income	$	26,972			$	14,140
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		65,502				78,249
Amortization		71,254				63,482
Remeasurement of tax receivable agreement		—				4,542
Loss on extinguishment of debt		1,418				7,716
Provision for credit losses		801				1,121
Provision for inventory obsolescence		859				2,539
Non-cash share-based compensation expense		15,066				10,127
Gain on sales and disposals of equipment		(793	)			(3,939	)
Deferred income taxes		(3,365	)			12,040
Changes in operating assets and liabilities:
Accounts receivable		3,420				(30,305	)
Inventories		(6,539	)			1,241
Other operating assets		(7,566	)			(5,392	)
Accounts payable		13,123				4,701
Other operating liabilities		(18,251	)			(21,849	)
Net cash provided by operating activities		161,901				138,413
Cash flows from investing activities:
Medical equipment purchases		(37,494	)			(23,912	)
Property and office equipment purchases		(20,374	)			(15,539	)
Proceeds from disposition of property and equipment		2,695				8,187
Acquisitions, net of cash acquired		(3,125	)			(450,198	)
Net cash used in investing activities		(58,298	)			(481,462	)
Cash flows from financing activities:
Proceeds under debt arrangements		20,000				233,052
Payments under debt arrangements		(146,173	)			(361,770	)
Payments of principal under finance lease liability		(6,676	)			(6,721	)
Payments of deferred financing costs		—				(229	)
Payments under tax receivable agreement		—				(748	)
Distributions to noncontrolling interests		(100	)			(138	)
Proceeds from exercise of stock options		2,949				380
Dividend and equity distribution payment		(908	)			(926	)
Proceeds from issuance of common stock		—				401,441
Stock issuance costs		—				(4,084	)
Shares forfeited for taxes		(14,488	)			—
Payments of contingent consideration		(321	)			—
Net cash (used in) provided by financing activities		(145,717	)			260,257
Net change in cash and cash equivalents		(42,114	)			(82,792	)
Cash and cash equivalents at the beginning of period		74,325				206,505
Cash and cash equivalents at the end of period	$	32,211			$	123,713

Use of non-GAAP information

This press release contains non-GAAP measures, including EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, Net Debt and Net Leverage Ratio. We use these internally as measures of operational performance, or liquidity, as applicable, and disclose them externally to assist analysts, investors and lenders in their comparisons of operational performance, valuation and debt capacity across companies with differing capital, tax and legal structures. We believe the investment community frequently uses these measures in the evaluation of similarly situated companies. Adjusted EBITDA is also used by the Company as a factor to determine the total amount of incentive compensation to be awarded to executive officers and other employees. EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, Net Debt and Net Leverage Ratio, however, are not measures of financial performance under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as alternatives to, or more meaningful than, net income as measures of operating performance or to cash flows from operating, investing or financing activities or to total debt as measures of liquidity or debt capacity. Since EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, Net Debt and Net Leverage Ratio are not measures determined in accordance with GAAP and are thus susceptible to varying interpretations and calculations, these measures, as presented, may not be comparable to other similarly titled measures of other companies. EBITDA, Adjusted EBITDA, and Adjusted Net Income do not represent amounts of funds that are available for management’s discretionary use. EBITDA and Adjusted EBITDA presented may not be the same as EBITDA and Adjusted EBITDA calculations as defined in the First Lien Credit Facilities. EBITDA is defined as earnings attributable to Agiliti, Inc. before interest expense, income taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA excluding non-cash share-based compensation expense, management fees and other non-recurring gains, expenses, or losses, transaction costs, remeasurement of the tax receivable agreement and loss on extinguishment of debt. LTM Adjusted EBITDA represents the last twelve months (“LTM”) of Adjusted EBITDA.

Agiliti, Inc. and Subsidiaries Non-GAAP Financial Measure: Adjusted EBITDA (in thousands)
		Three Months Ended September 30,							Nine Months Ended September 30,
			2022				2021			2022				2021
Net income attributable to Agiliti, Inc. and Subsidiaries		$	1,951			$	9,668		$	26,841			$	14,023
Interest expense			12,531				10,711			34,456				40,444
Income tax (benefit) expense (1)			(10,879	)			7,943			(5,672	)			13,832
Depreciation and amortization			42,170				46,861			133,711				138,676
EBITDA			45,773				75,183			189,336				206,975
Non-cash share-based compensation expense			4,859				4,360			15,066				10,127
Management and other expenses (2)			13,877				—			13,877				7,626
Transaction costs (3)			1,944				2,189			5,465				6,440
Tax receivable agreement remeasurement			—				197			—				4,542
Loss on extinguishment of debt (4)			—				—			1,418				10,116
Adjusted EBITDA		$	66,453			$	81,929		$	225,162			$	245,826

_____________________________
(1) Income tax (benefit) expense includes the $11.9 million tax benefit due to the release of the reserve and associated interest and penalties related to the Sizewise Acquisition.
(2) Management and other expenses represent (a) tax indemnification expense related to the Sizewise Acquisition;(b) management fees and buyout termination fee under the Advisory Services Agreement, which was terminated in connection with the initial public offering in 2021; and (c) non-recurring expenses.
(3) Transaction costs represent costs associated with potential and completed mergers and acquisitions and are primarily related to the Northfield and Sizewise acquisitions.
(4) Loss on extinguishment of debt for the nine months ended September 30, 2022 consists of the write-off of the unamortized debt discount related to the partial prepayment of the First Lien Term Loan. Loss on extinguishment of debt for the nine months ended September 30, 2021 consists of the write-off of the unamortized deferred financing costs and debt discount and an additional 1% redemption price related to the repayment of our Second Lien Term Loan and the write-off of the unamortized deferred financing cost related to the amendment of our Revolving Credit Facility.

Agiliti, Inc. and Subsidiaries Non-GAAP Financial Measure: Adjusted Net Income and Adjusted EPS (in thousands, except share and per share information)
		Three Months Ended September 30,								Nine Months Ended September 30,
			2022				2021				2022				2021
Net income attributable to Agiliti, Inc. and Subsidiaries		$	1,951			$	9,668			$	26,841			$	14,023
Amortization			23,080				21,497				68,209				60,427
Non-cash share-based compensation expense			4,859				4,360				15,066				10,127
Management and other expenses (1)			13,877				—				13,877				7,626
Transaction costs (2)			1,944				2,189				5,465				6,440
Tax receivable agreement remeasurement			—				197				—				4,542
Loss on extinguishment of debt (3)			—				—				1,418				10,116
Income tax benefit associated with pre-tax adjustments (4)			(19,663	)			(6,724	)			(37,908	)			(20,452	)
Adjusted net income		$	26,048			$	31,187			$	92,968			$	92,849
Weighted average shares outstanding - diluted			139,063				138,491				138,243				125,515
Adjusted EPS		$	0.19			$	0.23			$	0.67			$	0.74

_____________________________
(1) Management and other expenses include (a) tax indemnification expense related to the Sizewise Acquisition; (b) management fees and buyout termination fee under the Advisory Services Agreement, which was terminated in connection with the initial public offering in 2021; and (c) non-recurring expenses.
(2) Transaction costs represent costs associated with potential and completed mergers and acquisitions and are primarily related to the Northfield and Sizewise acquisitions.
(3) Loss on extinguishment of debt for the nine months ended September 30, 2022 consists of the write-off of the unamortized debt discount related to the partial prepayment of the First Lien Term Loan. Loss on extinguishment of debt for the six months ended September 30, 2021 consists of the write-off of the unamortized deferred financing costs and debt discount and an additional 1% redemption price related to the repayment of our Second Lien Term Loan and the write-off of the unamortized deferred financing cost related to the amendment of our Revolving Credit Facility.
(4) Income tax benefit associated with pre-tax adjustments represents the tax benefit or provision associated with the reconciling items between net income and adjusted net income and includes both the current and deferred income tax impact of the adjustments. To determine the aggregate tax effect of the reconciling items, we utilized statutory income tax rates ranging from 0% to 26%, depending upon the applicable jurisdictions of each adjustment. For the three and nine months ended September 30, 2022, the benefit includes $11.9 million due to the release of the reserve and associated interest and penalties related to the Sizewise Acquisition.

Agiliti, Inc. and Subsidiaries Non-GAAP Financial Measure: Net Debt and Net Leverage Ratio (in millions)
		September 30, 2022
Revolving Loan, due 2026		$	—
First Lien Term Loan, due 2026			1,056.9
Finance lease liability			23.9
Less: Unamortized Deferred Financing Costs and Debt Discount			(12.8	)
Total Debt		$	1,068.0
Less: Cash			(32.2	)
Net Debt		$	1,035.8
LTM Adjusted EBITDA		$	310.0
Net Leverage		3.3x

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005904/en/

Kate Kaiser

Corporate Communication and Investor Relations

kate.kaiser@agilitihealth.com

Source: Agiliti, Inc.

FAQ

What were Agiliti's Q3 2022 financial results?

Agiliti reported Q3 2022 revenue of $271 million, net income of $2 million, and diluted EPS of $0.01.

How did Agiliti's earnings compare to last year?

Net income decreased by $7.7 million from the previous year, and diluted EPS fell by $0.06.

What is Agiliti's updated 2022 financial guidance?

Agiliti revised its revenue guidance to $1.11 - $1.12 billion and adjusted EBITDA to $290-300 million.

When will Agiliti hold its Q3 2022 conference call?

The conference call is scheduled for November 10, 2022, at 5 p.m. Eastern Time.

What was the impact of contract delays on Agiliti's performance?

Agiliti acknowledged short-term headwinds related to delayed HHS contracts affecting their outlook.